Immunoglobulins A, D, G, and M

(redirected from and IgM)

Immunoglobulins A, D, G, and M

Synonym/acronym: IgA, IgD, IgG, and IgM.

Common use

To quantitate immunoglobulins A, D, G, and M as indicators of immune system function, to assist in the diagnosis of immune system disorders such as multiple myeloma, and to investigate transfusion anaphylaxis.

Specimen

Serum (1 mL) collected in a gold-, red-, or red/gray-top tube. Place separated serum in a standard transport tube within 2 hr of collection.

Normal findings

(Method: Nephelometry)
AgeConventional UnitsSI Units
Immunoglobulin A(Conventional Units × 0.01)
 Newborn1–4 mg/dL0.01–0.04 g/L
 1–9 mo2–80 mg/dL0.02–0.8 g/L
 10–12 mo15–90 mg/dL0.15–0.9 g/L
 2–3 yr18–150 mg/dL0.18–1.5 g/L
 4–5 yr25–160 mg/dL0.25–1.6 g/L
 6–8 yr35–200 mg/dL0.35–2 g/L
 9–12 yr45–250 mg/dL0.45–2.5 g/L
 Older than 12 yr40–350 mg/dL0.40–3.5 g/L
Immunoglobulin D(Conventional Units × 10)
 NewbornGreater than 2 mg/dLGreater than 20 mg/L
 AdultLess than 15 mg/dLLess than 150 mg/L
Immunoglobulin G(Conventional Units × 0.01)
 Newborn650–1,600 mg/dL6.5–16 g/L
 1–9 mo250–900 mg/dL2.5–9 g/L
 10–12 mo290–1,070 mg/dL2.9–10.7 g/L
 2–3 yr420–1,200 mg/dL4.2–12 g/L
 4–6 yr460–1,240 mg/dL4.6–12.4 g/L
 Greater than 6 yr650–1,600 mg/dL6.5–16 g/L
Immunoglobulin M(Conventional Units × 0.01)
 NewbornLess than 25 mg/dLLess than 0.25 g/L
 1–9 mo20–125 mg/dL0.2–1.25 g/L
 10–12 mo40–150 mg/dL0.4–1.5 g/L
 2–8 yr45–200 mg/dL0.45–2 g/L
 9–12 yr50–250 mg/dL0.5–2.5 g/L
 Greater than 12 yr50–300 mg/dL0.5–3 g/L

Description

Immunoglobulins A, D, E, G, and M are made by plasma cells in response to foreign substances. Immunoglobulins neutralize toxic substances, support phagocytosis, and destroy invading microorganisms. They are made up of heavy and light chains. Immunoglobulins produced by the abnormal proliferation of a single plasma cell (clone) are called monoclonal. Polyclonal increases result when multiple cell lines produce excessive amounts of antibody. IgA is found mainly in secretions such as tears, saliva, and breast milk. It is believed to protect mucous membranes from viruses and bacteria. The function of IgD is not well understood. For details on IgE, see the monograph titled “Immunoglobulin E.” IgG is the predominant serum immunoglobulin and is important in long-term defense against disease. It is the only antibody that crosses the placenta. IgM is the largest immunoglobulin, and it is the first antibody to react to an antigenic stimulus. IgM also forms natural antibodies, such as ABO blood group antibodies. The presence of IgM in cord blood is an indication of congenital infection.

This procedure is contraindicated for

    N/A

Indications

  • Assist in the diagnosis of multiple myeloma
  • Evaluate humoral immunity status
  • Monitor therapy for multiple myeloma
  • IgA: Evaluate patients suspected of IgA deficiency prior to transfusion. Evaluate anaphylaxis associated with the transfusion of blood and blood products (anti-IgA antibodies may develop in patients with low levels of IgA, possibly resulting in anaphylaxis when donated blood is transfused)

Potential diagnosis

Increased in

    IgA

  • Polyclonal

  • Chronic liver disease (pathophysiology is unclear)
  • Immunodeficiency states, such as Wiskott-Aldrich syndrome (inherited condition of lymphocytes characterized by increased IgA and IgE)
  • Inflammatory bowel disease (IgG and/or IgA antibody positive for Saccharomyces cerevisiae with negative perinuclear-antineutrophil cytoplasmic antibody is indicative of Crohn’s disease)
  • Lower gastrointestinal (GI) cancer (pathophysiology is unclear)
  • Rheumatoid arthritis (pathophysiology is unclear)
  • Monoclonal

  • IgA-type multiple myeloma (related to excessive production by a single clone of plasma cells)
  • IgD

  • Polyclonal (pathophysiology is unclear, but increases are associated with increases in IgM)

  • Certain liver diseases
  • Chronic infections
  • Connective tissue disorders
  • Monoclonal

  • IgD-type multiple myeloma (related to excessive production by a single clone of plasma cells)
  • IgG

  • (Conditions that involve inflammation and/or development of an infection stimulate production of IgG.)

  • Polyclonal

  • Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s syndrome
  • Chronic liver disease
  • Chronic or recurrent infections
  • Intrauterine devices (the IUD creates a localized inflammatory reaction that stimulates production of IgG)
  • Sarcoidosis
  • Monoclonal

  • IgG-type multiple myeloma (related to excessive production by a single clone of plasma cells)
  • Leukemias
  • Lymphomas
  • IgM

  • Polyclonal (humoral response to infections and inflammation; both acute and chronic)

  • Active sarcoidosis
  • Chronic hepatocellular disease
  • Collagen vascular disease
  • Early response to bacterial or parasitic infection
  • Hyper-IgM dysgammaglobulinemia
  • Rheumatoid arthritis
  • Variable in nephrotic syndrome
  • Viral infection (hepatitis or mononucleosis)
  • Monoclonal

  • Cold agglutinin hemolysis disease
  • Malignant lymphoma
  • Neoplasms (especially in GI tract)
  • Reticulosis
  • Waldenström’s macroglobulinemia (related to excessive production by a single clone of plasma cells)

Decreased in

    IgA

    Ataxia-telangiectasia Chronic sinopulmonary disease Genetic IgA deficiency

    IgD

    Genetic IgD deficiency Malignant melanoma of the skin Pre-eclampsia

    IgG

    Burns Genetic IgG deficiency Nephrotic syndrome Pregnancy

    IgM

    Burns Secondary IgM deficiency associated with IgG or IgA gammopathies

Critical findings

    N/A

Interfering factors

  • Drugs that may increase immunoglobulin levels include asparaginase, cimetidine, and narcotics.
  • Drugs that may decrease immunoglobulin levels include dextran, oral contraceptives, methylprednisolone (high doses), and phenytoin.
  • Chemotherapy, immunosuppressive therapy, and radiation treatments decrease immunoglobulin levels.
  • Specimens with macroglobulins, cryoglobulins, or cold agglutinins tested at cold temperatures may give falsely low values.

Nursing Implications and Procedure

Potential nursing problems

ProblemSigns & SymptomsInterventions
Hopelessness (Related to chronic illness; impaired functionality; prolonged pain and discomfort)Decreased affect; decreased response to stimuli; feeling of emptiness; alterations in sleep patterns and appetite; expressions of apathy; withdrawn; states life has no meaningAssess role of illness in relation to expressions of helplessness; assess grooming (energy to provide good personal hygiene); assess level of appetite; assess verbalization of helplessness; provide opportunities to express feelings in a safe environment; support development of a trusting relationship to decrease feelings of isolation; encourage verbalization of personal strengths and weaknesses; encourage realistic hope; assist in identification of coping skills
Protection (Related to failure of bone marrow; replacement of bone marrow by neoplastic cells; insufficient autoimmune response; chemotherapy; bone marrow transplant)Bleeding; infection; anemiaMonitor and trend HGB/HCT; monitor and trend platelets and red blood cells (RBCs); monitor for symptoms of infection; take temperature every 4 hr; institute bleeding precautions, soft toothbrushes, avoid aspirin, avoid IM or IV injections, coordinate laboratory draws to minimize venipuncture; administer prescribed steroids, erythropoietin; administer prescribed blood and blood products; avoid at-risk activities that could cause trauma; discuss exposure to microbes that could result in infection
Pain (Related to invasion of bone marrow and pathological fractures secondary to medication diagnosis [multiple myeloma])Self-report of pain; guarding; crying; moaning; sleeplessness; restlessness; emotional symptoms of distress; agitation; facial grimace; rocking motions; irritability; diaphoresis; altered blood pressure and heart rate; nausea; vomitingAssess pain characteristics, skeletal pain, low back, ribs; assess level of pain with movement; identify pain modalities that have relieved pain in the past; administer prescribed pain medication; monitor and trend vital signs; recommend use of nonpharmacologic pain management modalities, imagery, distraction, music, relaxation, correct body alignment

Pretest

  • Positively identify the patient using at least two unique identifiers before providing care, treatment, or services.
  • Patient Teaching: Inform the patient this test can assess the immune system by evaluating the levels of immunoglobulins in the blood.
  • Obtain a history of the patient’s complaints, including a list of known allergens, especially allergies or sensitivities to latex.
  • Obtain a history of the patient’s hematopoietic and immune systems, symptoms, and results of previously performed laboratory tests and diagnostic and surgical procedures.
  • Obtain a list of the patient’s current medications, including herbs, nutritional supplements, and nutraceuticals (see Effects of Natural Products on Laboratory Values online at DavisPlus).
  • Note any recent procedures that can interfere with test results.
  • Review the procedure with the patient. Inform the patient that specimen collection takes approximately 5 to 10 min. Address concerns about pain and explain to the patient that there may be some discomfort during the venipuncture.
  • Sensitivity to social and cultural issues, as well as concern for modesty, is important in providing psychological support before, during, and after the procedure.
  • Note that there are no food, fluid, or medication restrictions unless by medical direction.

Intratest

  • Potential complications: N/A
  • Avoid the use of equipment containing latex if the patient has a history of allergic reaction to latex.
  • Instruct the patient to cooperate fully and to follow directions. Direct the patient to breathe normally and to avoid unnecessary movement.
  • Observe standard precautions, and follow the general guidelines in Patient Preparation and Specimen Collection. Positively identify the patient, and label the appropriate specimen container with the corresponding patient demographics, initials of the person collecting the specimen, date, and time of collection. Perform a venipuncture.
  • Remove the needle and apply direct pressure with dry gauze to stop bleeding. Observe/assess venipuncture site for bleeding or hematoma formation and secure gauze with adhesive bandage.
  • Promptly transport the specimen to the laboratory for processing and analysis.

Post-Test

  • Inform the patient that a report of the results will be made available to the requesting health-care provider (HCP), who will discuss the results with the patient. A patient with IgA deficiency should not receive gamma globulin. Administration of gamma globulin may initiate sensitization of the immune system that could result in an anaphylactic shock during a subsequent RBC product transfusion, related to instigation by donor IgA in the product. IgA deficiency is a lifelong condition, if transfusion is necessary and products from an IgA-deficient donor are unavailable, washed RBCs can be used to decrease the risk of transfusion reaction.
  • Depending on the results of this procedure, additional testing may be performed to evaluate or monitor progression of the disease process and determine the need for a change in therapy. Evaluate test results in relation to the patient’s symptoms and other tests performed.
  • Patient Education

    • Reinforce information given by the patient’s HCP regarding further testing, treatment, or referral to another HCP.
    • Answer any questions or address any concerns voiced by the patient or family.
    • Provide information on the disease process as it relates to altered laboratory results.
  • Expected Patient Outcomes

    • Knowledge
    • States understanding of the importance of notifying the HCP if the pain management regime is ineffective
    • States understanding that a combination of pain management modalities may be most effective in managing pain
    • Skills
    • Describes appropriate use of pain scale for quantifying the severity of pain experienced
    • Demonstrates proficiency in using a selected nonpharmacological pain management strategy to decrease pain intensity
    • Attitude
    • Complies with the recommendation to try using nonpharmacological measures to decrease pain
    • Complies with the recommendation to take pain medication around the clock to decrease the risk of peak pain periods

Related Monographs

  • Related tests include ALT, anion gap, ANA, bilirubin, biopsy bone, biopsy bone marrow, biopsy liver, biopsy lymph node, blood groups and antibodies, cold agglutinin, CBC, CBC WBC count and differential, Coomb’s antiglobulin (direct and indirect), cryoglobulin, ESR, fibrinogen, IFE, quantitative immunoglobulin levels, GGT, LAP, liver and spleen scan, beta-2-microglobulin, platelet antibodies, protein total and fractions, RF, and uric acid.
  • Refer to the Hematopoietic and Immune systems tables at the end of the book for related tests by body system.
References in periodicals archive ?
5mg/dl, increase in serum transaminases more than twice than normal with reactive hepatitis E immunoglobulin G (IgG) and IgM were included.
ELISA test for dengue IgG and IgM was performed two time in order to confirm the dengue cases.
CHIKV infection is currently identified by viral genome detection, using reverse transcription PCR (RT-PCR), viral culture, and serologic testing for IgG and IgM by indirect immunofluorescence (IFA) or ELISA.
Tenders are invited for Reagents for performing tests for Lyme disease IgG and IgM in serum and cerebrospinal fluid - CSF by Western blot positive control sera Borrelia IgG positive control sera Borrelia IgM negative control sera Borrelia burgdorferi IgG / IgM analyzer with a lease to carry out research in borreliosis IgG and IgM in serum and cerebrospinal fluid - CSF by Western blot for 3 years (36 months).
Dengue antibodies IgG and IgM were performed by ICT method using a device manufactured by Standard Diagnostic, INC (SD) Korea.
Phase of Primary infection Secondary infection illness Viremic NS1 positive No isolated viremic phase since anamnestic IgG response often present at the onset of illness Viremia-immune NS1 positive NS1 positive overlap Plus Plus One of the following: One of the following IgM positive (>40 units) IgG positive (>100 units) and IgG negative and IgM negative IgM/IgG optical density IgM/IgG optical density ratio > cut-off value ratio < cut-off value of assay (a) of assay (a) Immune IgM positive (>40 units) IgM/IgG optical density and IgG negative ratio < cut-off value of assay (a) OR IgM/IgG optical density ratio > cut-off value of assay (a) IgM and IgG detection by enzyme-linked immunosorbent assay (ELISA).
Simultaneous measurement of total antibody and IgM can be performed and may prove to be beneficial in helping physicians correctly interpret HAV serology.
The MAT detects both IgG and IgM antibodies (17) but the MAT titers are usually low during the acute stage of the disease and, hence, diagnosis based on a single serum sample is difficult (18).
Blood samples collected from all children were tested for the presence of specific IgG and IgM antibodies to T.